Showing all 5 results
Glibenclamide & Metformin Hydrochloride Tablets
FreeProduct Composition & Standard Strengths
We supply this product in standardized Fixed-Dose Combinations (FDCs) designed for flexible clinical titration.
Active Ingredient Standard Strengths (per Tablet) Primary Clinical Function Metformin HCl 400 mg / 500 mg The Foundation: Reduces glucose production. Glibenclamide (Glyburide) 2.5 mg / 5 mg The Stimulator: Enhances insulin secretion. Excipients Pharma Grade The Matrix: Ensures stability of the FDC. Metformin Hydrochloride & Glimepiride Tablets
FreeProduct Composition & Strength
We supply this product in Bilayer Tablets or Matrix Tablets packed in Alu-Alu or PVC/PVDC Blisters.
Product Strength Metformin HCl (SR) Glimepiride Common Name 500/1 mg 500 mg 1 mg G1 Tablet 500/2 mg 500 mg 2 mg G2 Tablet 1000/2 mg 1000 mg 2 mg Forte / DS Tablet 1000/4 mg 1000 mg 4 mg High Strength Metformin Tablet
FreeProduct Composition & Portfolio Range
We manufacture Metformin SR in the full spectrum of internationally recognized therapeutic strengths, utilizing a specialized slow-release scaffold to reduce dosing frequency to once daily.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Metformin Hydrochloride IP / BP / USP 500 mg Hydrophilic Dual-Polymer Sustained-Release Initial Titration: For low-dose introductory management and early-stage Type 2 stabilization. Metformin Hydrochloride IP / BP / USP 750 mg Hydrophilic Dual-Polymer Sustained-Release Intermediate Scaling: Step-up strength to optimize glycemic indices without increasing tablet count. Metformin Hydrochloride IP / BP / USP 1000 mg Hydrophilic Dual-Polymer Sustained-Release High-Potency Maintenance: Maximizes daily therapeutic saturation in an elegant, once-daily single tablet format. Metformin Tablets
FreeProduct Composition & Available Specifications
We supply Metformin Hydrochloride across the full spectrum of compendial strengths and advanced kinetic delivery platforms to optimize patient compliance and reduce gastrointestinal side effects.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Metformin Hydrochloride USP / BP / IP 500 mg Oral Solid Immediate-Release Film-Coated Tablet Introductory Titration: Baseline format designed for low-dose introductory management and gradual step-up scaling. Metformin Hydrochloride USP / BP / IP 850 mg Oral Solid Immediate-Release Film-Coated Tablet High-Density Single Dose: Intermediate strength optimized for achieving target daily therapeutic thresholds with fewer tablets. Metformin Hydrochloride USP / BP / IP 1000 mg Oral High-Mass Immediate-Release Tablet Maximal Saturation Therapy: High-strength configuration calibrated for advanced glycemic control and high-dose combinations. Metformin Hydrochloride USP / BP / IP 500 mg / 1000 mg SR Extended/Sustained-Release Hydrophilic Polymer Matrix Premium GI-Comfort Compliance: Once-daily formulation utilizing a dual-layer hydrogel matrix to release active drug slowly, completely eliminating gastrointestinal distress. Pioglitazone Tablets
FreePioglitazone Tablets IP 15 mg
Each Uncoated tablet contains :
Pioglitazone Hydrochloride IP
Eq. To Pioglitazone 15 mgPioglitazone Tablets IP 30 mg
Each Uncoated tablet contains :
Pioglitazone Hydrochloride IP
Eq. To Pioglitazone 30 mgPioglitazone With Metformin Tablet
Each Film Coated Tablet contains :
Pioglitazone Hydrochloride IP
Eq. to Pioglitazone 15 mg
Metformin Hydrochloride IP 500 mgUsage: – Type 2 diabetes mellitus
Category: – Anti Diabetic drugs
Therapeutic category: – Anti Diabetic
